Brief: Gc Cell's AB-201 Cancer Treatment To Begin Phase 1 Trials Using Lunit Ai Platform
08/01/2024 17:28
Jan 8 (Reuters) - GC Biopharma Corp 006280.KS :
* GC CELL'S PROMISING AB-201 CANCER TREATMENT TO BEGIN PHASE
1
TRIALS USING LUNIT AI PLATFORM
Source text for Eikon: ID:nPn57Yplva
Further company coverage: 006280.KS
((Reuters.Briefs@thomsonreuters.com;))
Recent news on GC Biopharma
See all newsBrief: Gc Biopharma Q2 Operating. Profit 1.7 Billion Won, Down 93.8% Y/Y
Brief: Gc Biopharma Corp 006280.Ks - Q1 Operating. Profit 11.7 Billion Won, Up 46% Y/Y
Brief: Green Cross Corp Q3 Operating Profit 29.2 Billion Won, Down 26.3% From Year Earlier
Brief: GC Biopharma gets CMO rights for shingles vaccine from Curevo Vaccine
Brief: Gc Biopharma Receives Marketing Authorization For Barycela In Vietnam